Having successfully partnered Nubeqa with a pharma major in Bayer AG, Orion Corporation has teamed up with an even bigger player, Merck & Co., Inc., for another prostate cancer candidate, picking up a big upfront into the bargain.
The Finland-based group has unveiled a licensing deal with Merck for ODM-208, a first-in-class CYP11A1 inhibitor which is in a Phase II trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)